Gout, a painful form of inflammatory arthritis, is set to become far more common in the coming decades. According to projections, the number of cases globally is expected to rise significantly over the next twenty-five years, driven by aging populations, obesity, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with gout, and an even larger group—44 million people—have uric acid levels above the normal range, putting them at risk for developing the disease. This looming public health challenge underscores the urgent need for better treatment options, as current therapies often come with debilitating side effects that lead patients to stop taking them.
Existing gout medications, particularly oral xanthine oxidase inhibitors (XOIs), are the standard of care but are not without significant drawbacks. They can cause severe gastrointestinal issues, kidney toxicity, and cardiovascular risks, especially with long-term or high-dose use. Moreover, some treatments initially trigger more gout flare-ups, further discouraging adherence. Approximately 3% to 5% of patients cannot tolerate XOIs at all, and these drugs carry boxed warnings for cardiovascular risk. This leaves a substantial unmet need for safer, more tolerable therapies that patients can stick with over the long term.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is aiming to fill that gap with its proprietary drug candidate, XORLO™. XORLO is a novel formulation of oxypurinol that utilizes a liposomal delivery system to overcome the historically poor oral absorption of the compound. This approach allows for effective uric acid lowering at substantially lower total daily doses, minimizing toxic-level exposure and the severe gastrointestinal side effects associated with high-dose traditional therapies. The company believes XORLO could offer a differentiated treatment option for gout sufferers. Investors and industry observers can track the company’s progress through resources such as XORTX.
XORTX is making tangible strides toward bringing XORLO to market. The company recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This study is being advanced based on positive prior clinical results and discussions with the FDA. The production of GMP drug and clinical supply tablets representative of the intended commercial product has already begun, with contract manufacturing of pure oxypurinol drug substance underway. These manufacturing milestones are critical because they demonstrate the company’s readiness to produce commercial-grade supply, a key requirement for regulatory approval.
Regulatory progress is also accelerating. XORTX is working toward a new drug application submission to the FDA for XORLO. The company has prepared a new Investigational New Drug (IND) application for submission in the fourth quarter of 2026, which outlines its clinical development plan. Once the two-part clinical trial is complete, XORTX intends to request a pre-NDA meeting with the FDA and simultaneously prepare an NDA submission while engaging in pre-commercialization activities. The company is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO. “Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
The implications of XORTX’s progress are significant. With gout prevalence on the rise and existing therapies limited by tolerability and safety concerns, a new treatment that improves adherence could address a major gap in care. If XORLO successfully navigates clinical trials and FDA review, it could provide patients with a better-tolerated option, reduce the burden of gout-related complications, and potentially lower healthcare costs associated with poorly managed disease. For XORTX, a successful NDA submission would mark a transformation from a clinical-stage company to a commercial one, with substantial revenue potential. As the company advances its manufacturing and regulatory efforts, the broader market will be watching closely to see if XORLO can become the new standard for gout management. This content was originally published on Benzinga and is available on www.newmediawire.com.
